NCT06481826Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 12 Jun 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06481826
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 Jan 2024 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with known active infection, or reactivation of a latent infection
- Patient with active autoimmune disease or immune deficiency
Lab values
- severe organ failure：LVEF\<40%；DLCO\<40%；eGFR\<30ml/min；Bilirubin≥3ULN
Other
- Pregnancy or breastfeeding
- Patients who are dependent on the sponsor, the investigator or the trial site
Who the study is looking for
- Histologically-confirmed DLBCL
- Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy
- Participants must have measurable disease
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.